1、Breaking the Bottleneck of Preclinical Drug Screening – Customized Cell Banks and Animal Models Accelerate Accurate Efficacy Evaluation

Industry Pain Point：Insufficient predictability of traditional drug screening models and low clinical conversion rate.

Value Proposition: Relying on more than 1,000 standardized cell lines and over 50 disease animal models, we provide a highly human microenvironment-simulating efficacy evaluation platform, shortening the R&D cycle by more than 30%.

2、Service Overview

In innovative drug R&D, in vitro drug efficacy evaluation is a core link in preclinical research. Due to species differences and microenvironment distortion, traditional models lead to deviations in efficacy prediction (e.g., the disconnection between subcutaneous xenografts and clinical responses). Jennio focuses on cell banks and animal cell line models, and constructs a high-predictability efficacy platform through humanized tumor cell lines, primary cells and PDX models to solve the problem of “seed-soil mismatch” and significantly reduce the risk of clinical failure.

3、Our Services

1. Cell Bank Services
   • Commercial cell banks: Covering 15 cancer types including lung cancer, liver cancer and leukemia, with more than 1,000 human/murine cell lines, supporting high-throughput primary drug screening.
   • Primary tumor cell banks: More than 100 Chinese human-derived primary tumor cells, retaining patient tumor heterogeneity, suitable for individualized drug sensitivity testing.
   • Custom tool cells: Gene-edited cells (CRISPR-Cas9 knockout/overexpression), drug-resistant strains, fluorescent tracer strains, meeting the needs of target validation.

2. Animal Cell Line Models

• CDX models: Subcutaneous/orthotopic/metastatic tumor models, supporting real-time monitoring via in vivo
• Example: HepG2-luc orthotopic liver cancer model verifies the anti-tumor effect of lenvatinib.
• In vitro-in vivo linkage platform: One-stop service for cell screening → animal model efficacy verification, shortening the data chain.

3. In Vitro Efficacy Evaluation

• Target detection: Bioinformatic prediction/WB detection of cellular targets, Provide cellular target expression information and in vitrocell drug screening services.
• Cellular functional detection: MTT/CCK-8/CTG proliferation assays, Transwell migration/invasion assays, flow cytometry analysis of apoptosis/cell cycle.
• 3D organoid drug sensitivity: QuiGue™-Quick3D rapid in vitro screening, providing dose-response curves within 7 days.

4、Technical Platforms and Advantages

1. Core Platforms

• PDX model platform: A living sample bank of more than 200 cases, with a transplantation success rate of over 72%, retaining clinical pathological characteristics.
• Gene editing platform: CRISPR-Cas9 tool cell construction, supporting rapid target validation.
• In vivoimaging platform: Real-time monitoring of tumor growth kinetics via optical imaging.

2. Differentiated Advantages

• Cross-species consistency: Humanized models restore the clinical microenvironment, increasing the efficacy correlation by 40%.
• Standardized delivery: STR identification and sterility testing ensure cell quality, and the data meets the requirements for FDA applications.

5、Service Process

1. Demand communication: Feedback of customized solutions (e.g., model selection, detection indicators) within 1 working day.
2. Experiment execution:

• Cell experiments: Provision of raw data (flow cytometry plots, fluorescence images) and statistical analysis.
• Animal models: Weekly update of tumor growth curves/survival rate data.

3. Data delivery: Output of GLP-aligned standard reports (including raw data and pathological sections) within 10-15 working days.

6、Quality Control and Compliance

• Qualification certification: SPF animal facility (GB 14925), BSL-2 laboratory.
• Quality control standards: Cell lines undergo STR identification and mycoplasma testing; animal experiments follow AAALAC welfare guidelines.
• Data traceability: Electronic experimental records, supporting raw data review.

7、Case Demonstration

Case 1: PDX Models Accelerate Pancreatic Cancer Drug Decision-Making

• Challenge: Patients develop chemoresistance, with no effective treatment options available.
• Solution: In vivo PDX drug sensitivity screening (oxaliplatin + 5-Fu combination therapy).
• Result: 78% tumor inhibition rate, supporting clinical medication decision-making.

Case 2: CAR-T Cell Efficacy Evaluation

• Model: Nalm6 leukemia mouse model.
• Data: 700% reduction in fluorescent signal in the treatment group (vs. the control group), verifying the in vivo tumor suppressive effect.

8、Cooperation Advantages

• Full-cycle support: From target discovery (cell bank screening) to IND application (CDX/PDX efficacy data).
• Cost optimization: Shared model resources, reducing the cost of single projects by 30%.
• Global compliance: Data complies with ICH and NMPA regulations, supporting simultaneous applications in China and the US.

9、FAQ

Q: Do you support the customization of models for rare cancer types?

A: Yes! Relying on the Chinese human-derived primary tumor cell bank, we can construct models for thyroid cancer, osteosarcoma and other rare cancers.

Q: Can data delivery be expedited?

A: An expedited channel is available, with key data delivered within 3 days for cell experiments and 2 weeks for animal models.

10、Laboratory Highlights

• Ten-thousand-grade cell culture room: Supporting large-scale cell expansion and quality control.
• Automated detection platform: High-throughput screening of more than 1,000 samples per day.

→ Click to view the laboratory panorama

View More

11、Contact Us

Consult Now:

• Email: 3691125803@qq.com
• Tel: +86 18802035152

Limited-time Benefits:

• Free access to Technical White Paper on PDX Model Construction→ [Download Link]
• First order experience: 20% discount on cell bank screening services!